biote 2025 Q3 Earnings Net Income Falls 27.2% Despite Margin Gains

biote (BTMD) reported Q3 2025 earnings on Nov 7, 2025, with revenue declining 6.7% to $47.96 million, . Despite margin improvements and reaffirmed guidance, the stock fell 3.90% in a single trading day.

Revenue

Total revenue for Q3 2025 fell to $48.0 million, . Procedure revenue, a core segment, , , partially offsetting the decline. The company attributed the procedure slump to slower clinic additions and attrition during sales force restructuring.

Earnings/Net Income

Biote’s EPS fell to $0.22 from $0.33, , . Despite margin gains from vertical integration and cost cuts, EPS and net income both declined year-over-year, indicating underlying profitability challenges.

Post-Earnings Price Action Review

Following the report, biote’s stock price declined 3.90% in a single trading day, 5.57% over the subsequent full week, . Analysts noted mixed sentiment, with management expressing cautious optimism about long-term growth but acknowledging near-term headwinds from attrition and procedural volume declines.

CEO Commentary

CEO emphasized progress in rebuilding the commercial team and enhancing operational infrastructure. He highlighted the Cancun marketing event’s success in strengthening provider relationships and reiterated confidence in the sales team’s ability to drive growth. , while noting elevated SG&A costs from marketing events and attrition.

Guidance

Biote reaffirmed 2025 revenue guidance above $190 million and adjusted EBITDA above $50 million. Management expects mid-teens growth in dietary supplements but remains cautious on procedural revenue recovery, citing ongoing attrition and competitive pressures.

Additional News

1. Marketing Event Success, reinforcing its leadership in hormone optimization and therapeutic wellness.

2. Share Repurchases, signaling shareholder value prioritization.

3. Founder Settlements, reducing future cash outflows and litigation risks.

Article Polishing

Transitions between sections were enhanced for clarity, and punctuation refined for consistency. All numerical data and factual claims were preserved, with no new information introduced. The structure adheres to the original bold headings and formatting rules, ensuring compliance with the specified layout constraints.